Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
| Autor: | Elizabeth M. Van Cott, Allison Burnett, Adam Cuker, Scott Kaatz, Darren M. Triller, Jack Ansell, Diane Wirth, Mark Crowther |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Rivaroxaban business.industry Anticoagulants Idarucizumab Hematology Antibodies Monoclonal Humanized Prothrombin complex concentrate Recombinant Proteins Dabigatran Factor Xa Practice Guidelines as Topic medicine System level Humans Apixaban Intensive care medicine business medicine.drug Andexanet alfa |
| Zdroj: | American Journal of Hematology. 94:697-709 |
| ISSN: | 1096-8652 0361-8609 |
| DOI: | 10.1002/ajh.25475 |
| Popis: | Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text